Pantheon, LGT back early-stage biotech restructuring

The deal involving Medicxi was based around six assets and completed at a premium to NAV, co-founder Francesco De Rubertis told Secondaries Investor.

DealsInvestorsManagersEuropeFeaturedGP-LedsLegal & Regulation